

Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

Table 2d. Annual reported cases* of notifiable diseases, by region and reporting area, United States, U.S. Territories and Non-U.S. Residents, 2023

Reporting Area	Brucellosis	Campylobacteriosis	Candida auris		Carbapenemase-producing organisms (CPO), total\$,†	Chancroid	Chlamydia trachomatis infection
			Clinical‡	Screening‡			
U.S. Residents, excluding U.S. Territories	145	81,547	3,200	4,366	6,910	4	1,648,444
New England	3	3,539	1	—	119	—	54,454
Connecticut	—	838	—	—	—	—	13,197
Maine	—	230	—	—	51	—	3,034
Massachusetts	2	1,659	—	—	—	—	28,895
New Hampshire	—	337	1	—	26	N	2,756
Rhode Island	1	275	—	—	39	—	5,265
Vermont	—	200	—	—	3	—	1,307
Middle Atlantic	15	12,248	41	56	584	—	199,573
New Jersey	4	2,377	—	—	—	—	35,689
New York (excluding New York City)	4	3,249	—	—	—	—	42,329
New York City	4	3,685	—	—	262	—	66,955
Pennsylvania	3	2,937	41	56	322	—	54,600
East North Central	17	9,921	855	1,512	2,810	1	226,199
Illinois	13	2,769	474	685	719	—	69,992
Indiana	—	1,244	112	175	400	—	33,693
Michigan	1	1,736	110	325	340	1	43,115
Ohio	3	2,574	151	318	1,306	—	54,411
Wisconsin	—	1,598	8	9	45	—	24,988
West North Central	4	6,906	10	34	276	—	97,275
Iowa	—	1,357	6	34	88	—	13,687
Kansas	1	974	—	—	84	—	13,345
Minnesota	2	1,825	4	—	86	—	21,777
Missouri	1	1,537	—	—	—	—	30,892
Nebraska	—	611	—	—	—	—	9,266
North Dakota	—	147	—	—	12	—	3,421
South Dakota	—	455	—	—	6	—	4,887
South Atlantic	21	13,989	412	539	891	—	378,344
Delaware	—	210	23	46	16	—	5,703
District of Columbia	—	146	—	—	—	—	8,338
Florida	10	4,719	N	—	N	—	112,804
Georgia	7	1,961	191	212	326	—	71,294
Maryland	2	1,289	88	172	—	—	35,836
North Carolina	—	2,560	18	8	184	—	65,867
South Carolina	2	814	—	—	—	—	32,889
Virginia	—	1,749	88	100	273	—	41,206
West Virginia	—	541	4	1	92	—	4,407
East South Central	2	4,140	71	299	228	—	107,987
Alabama	1	879	N	—	N	—	33,260
Kentucky	—	1,258	—	—	—	—	17,252
Mississippi	1	657	—	—	228	—	20,603
Tennessee	—	1,346	71	299	—	—	36,872
West South Central	24	8,281	522	777	24	—	223,183
Arkansas	—	814	—	—	—	—	17,781
Louisiana	3	959	26	44	24	—	36,242
Oklahoma	2	1,694	—	—	—	—	19,104

Table 2d. Annual reported cases* of notifiable diseases, by region and reporting area, United States, U.S. Territories and Non-U.S. Residents, 2023

Reporting Area	Brucellosis	Campylobacteriosis	Candida auris		Carbapenemase-producing organisms (CPO), total§,¶	Chancroid	Chlamydia trachomatis infection
			Clinical†	Screening‡			
Texas	19	4,814	496	733	U	—	150,056
Mountain	7	6,124	734	1,144	1,034	—	115,738
Arizona	3	1,361	124	77	854	—	41,058
Colorado	1	1,717	—	—	—	—	25,571
Idaho	1	618	—	—	—	—	5,785
Montana	—	438	—	—	3	—	3,655
Nevada	—	319	607	1,064	101	—	15,766
New Mexico	1	540	—	—	—	—	11,071
Utah	1	881	3	3	75	—	11,003
Wyoming	—	250	—	—	1	—	1,829
Pacific	52	16,399	554	5	944	3	245,691
Alaska	—	163	1	1	—	—	5,117
California	39	11,987	551	—	808	3	191,292
Hawaii	7	939	1	—	24	—	6,251
Oregon	4	1,116	1	2	26	—	15,344
Washington	2	2,194	—	2	86	—	27,687
U.S. Territories	1	77	—	—	182	—	7,139
American Samoa	—	—	—	—	—	—	344
Commonwealth of Northern Mariana Islands	—	—	—	—	—	—	229
Guam	1	14	—	—	—	—	754
Puerto Rico	—	63	—	—	182	—	5,195
U.S. Virgin Islands	—	—	—	—	—	—	617
Non-U.S. Residents	3	4	—	—	1	—	51
Total	149	81,628	3,200	4,366	7,093	4	1,655,634

—: No reported cases — The reporting jurisdiction did not submit any cases to CDC.

N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.

U: Unavailable — The data are unavailable.

* Cases are assigned to the reporting jurisdiction submitting the case to NNDSS if the case's country of usual residence is the United States, a U.S. territory, unknown, or country is not reported; otherwise, the case is assigned to the Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions because this data element is only available in the HL7 generic version 2 and disease-specific message mapping guides. If a jurisdiction sends data in legacy formats, they are not able to send this information. For further information on interpretation of these data, see the [Guide to Interpreting Provisional and Finalized NNDSS Data](#).

† Beginning in 2023, only confirmed cases of *Candida auris* clinical are published to align with CSTE position statement 22-ID-05, whereas in previous years, confirmed and probable case classification statuses were published. Additionally, there may be case count discrepancies of *Candida auris* clinical cases reported by the NNDSS and the CDC's Mycotic Diseases Branch due to differences in data sources, reporting and aggregation methods. Please refer to the Mycotic Diseases Branch's [Tracking C. auris | Candida auris \(C. auris\) | CDC for Candida auris case data](#) reported by jurisdictions. These data are submitted to the CDC separately of NNDSS by jurisdictions and are published by location of the facility. Please also see Note #8.

‡ Beginning in 2023, *Candida auris* screening was added as a nationally notifiable condition, and confirmed cases are published to align with the approved CSTE position statement 22-ID-05. Additionally, there may be case count discrepancies of *Candida auris* screening cases reported by the NNDSS and the CDC's Mycotic Diseases Branch due to differences in data sources, reporting and aggregation methods. Please refer to the Mycotic Diseases Branch's [Tracking C. auris | Candida auris \(C. auris\) | CDC for Candida auris case data](#) reported by jurisdictions. These data are submitted to the CDC separately of NNDSS by jurisdictions and are published by location of the facility. Please also see Note #8.

§ Beginning in 2023, cases began to be reported as carbapenemase-producing organisms, clinical or carbapenemase-producing organisms, screening. In previous years, only carbapenemase-producing carbapenem-resistant *Enterobacteriaceae* (CP-CRE) cases were reported.

¶ CPO total is the sum of CP-CRE cases reported in MMWR year 2023, CPO, clinical cases, and CPO, screening cases.

Notes:

1. These are **annual** cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. Source datasets for the 2023 annual tables were officially closed on November 7, 2024.

2. The list of national notifiable infectious diseases and conditions for 2023 and their national surveillance case definitions are available by navigating to the [Surveillance Case Definitions | CDC](#) web page, selecting "2023" for the notifiable condition list year, checking "Infectious" conditions, and clicking "Get Notifiable List by Year". Publication criteria for the finalized 2023 data are available at <https://www.cdc.gov/nndss/infectious-disease/notice-to-data-users.html>. See also [Guide to Interpreting Provisional and Finalized NNDSS Data](#).

3. Population estimates for incidence rates are July 1st, 2023 postcensal estimates of the resident population of the United States for July 1, 2020, to July 1, 2023, by year, county, single year of age (range: 0 to 85+ years), bridged-race (American Indian or Alaska Native, Asian or Pacific Islander, Black or African American, White), Hispanic ethnicity (Hispanic or Latino, not Hispanic or Latino), and sex (Female, Male), prepared under a collaborative arrangement with the U.S. Census Bureau and the National Cancer Institute (NCI). The "Vintage 2023" population estimates for years 2020–2023 were released February 2025 by the National Cancer Institute at <https://seer.cancer.gov/popdata/>. For more information, see <https://seer.cancer.gov/popdata/singleages.html>. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.

4. Annual tables for 2016 and later years are available on [CDC WONDER's NNDSS Annual Summary Data Query](#).

5. Annual summary reports from 1993–2015 are available as published in the [Morbidity and Mortality Weekly Report](#).

6. NNDSS annual tables since 1952 are available at [CDC Stacks](#). To find them, search for "NNDSS" under Collections. Once in NNDSS Collections, navigate to the "Resource Type Specific" section on the left-hand side and select "Annual Reports" (1952–2015) or "Annual Tables" (2016–present).

7. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a national notifiable infectious condition is associated with a specific age restriction, the same

restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

Age restrictions in the numerator and denominator are applied for the following childhood conditions:

Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)
Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)
Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years)
Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)
Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)
Infant botulism (age restriction in numerator and denominator is <1 year)
Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)
Perinatal hepatitis B infection (age restriction in numerator is ≤24 months; however, rates will not be calculated due to population estimates not being available for the specific sub-population required to align with the defined age restriction criteria)
Perinatal hepatitis C infection (age restriction in numerator is ≤36 months; however, rates will not be calculated due to population estimates not being available for the specific sub-population required to align with the defined age restriction criteria).

Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2023 (National Center for Health Statistics [Natality 2023](#), as compiled from data provided by the Vital Statistics Cooperative Program). Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases.

8. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).

Suggested Citation:

Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, 2023 Annual Tables of Infectious Disease Data. Atlanta, GA: CDC Office of Public Health Data, Surveillance, and Technology, 2025. Available at: <https://www.cdc.gov/nndss/infectious-disease/>.

Acknowledgment:

CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., healthcare providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.

National Notifiable Diseases Surveillance System